Treatment Guide

Anxiety Disorders Treatment Options: First-Line to Next Steps

CBT and SSRI or SNRI antidepressants are first-line anxiety disorders treatment options, yet only 9.8% of people with one get adequate care, 2018 data show.

Mental Health Stats Research Team 6 min read

Key Takeaways

  • In 41 placebo-controlled trials, cognitive behavioral therapy had a moderate effect on symptoms of anxiety and related disorders (Hedges' g = 0.56)[1].g = 0.56[1]
  • SSRIs and SNRIs are the first-line medicines for anxiety disorders, and their anti-anxiety effect usually begins after 2 to 4 weeks[2].2 to 4 weeks[2]
  • In a 488-child trial, 80.7% improved with CBT plus sertraline, compared with 59.7% on CBT alone, 54.9% on sertraline alone and 23.7% on placebo[3].80.7%[3]
  • Across 28 relapse-prevention trials, 36.4% of antidepressant responders relapsed after switching to placebo, compared with 16.4% who stayed on medication[4].36.4% vs. 16.4%[4]
  • In surveys across 21 countries, only 9.8% of people with a past-year anxiety disorder received possibly adequate treatment[5].9.8%[5]

What Are the Treatment Options for Anxiety Disorders?

The main anxiety disorders treatment options are psychotherapy, chiefly cognitive behavioral therapy (CBT) with exposure, and medication, with SSRIs and SNRIs as the first-line drugs, used alone or together, for anxiety disorders such as generalized anxiety disorder, panic disorder and social anxiety disorder[2]. A 2017 guideline-based review lists pregabalin, tricyclic antidepressants and buspirone among the further options[2].

The U.S. Preventive Services Task Force, which in 2023 recommended anxiety screening for adults 64 and younger, names cognitive behavioral, interpersonal, family, and acceptance and commitment therapy as psychotherapy options[6]. Its medication list covers antidepressants, antihistamines, beta-blockers, anticonvulsants and benzodiazepines[6].

Most care is outpatient. Hospital admission is reserved for situations such as suicidality, no response to standard treatments, or serious co-occurring conditions like major depression, personality disorders or substance use disorders[2].

Guidelines also call for psychoeducation: explaining the diagnosis, the bodily symptoms of anxiety and how each treatment is thought to work[2]. The choice among options weighs patient preference, past treatment, severity, co-occurring conditions, local availability, wait times for therapy and cost[2].

First-line treatment

The option clinical guidelines recommend trying first, based on trial evidence and the balance of benefit and risk. For anxiety disorders, SSRIs and SNRIs are first-line medicines because of their favorable benefit/risk balance, and CBT is the psychotherapy with the highest level of evidence[2].

Related Terms

second-line treatment
treatment-resistant anxiety
psychoeducation
relapse prevention

Source: Bandelow et al., Dialogues in Clinical Neuroscience, 2017

Anxiety Disorders Treatment Options at a Glance

OptionExamplesRole in careTrial support
CBT with exposureIndividual, group or internet-guidedFirst-line psychotherapyAll anxiety disorders
SSRIsEscitalopram, sertraline, paroxetineFirst-line medicationPanic disorder, GAD, social anxiety
SNRIsVenlafaxine, duloxetineFirst-line medicationVenlafaxine: panic, GAD, social anxiety; duloxetine: GAD
PregabalinCalcium modulatorAlternative medicationGAD, social anxiety
Tricyclic antidepressantClomipramineAlternative medicationPanic disorder
BuspironeAzapironeAlternative medicationGAD
BenzodiazepinesAlprazolam, clonazepam, lorazepamNot first-line; limited or exceptional useFast-acting; dependence risk
Psychodynamic therapyInsight-oriented talk therapyAlternative psychotherapyFewer, lower-quality trials than CBT
ExerciseAerobic trainingAdd-on onlyPanic disorder: no better than relaxation

Treatment options for adult anxiety disorders, their role in guideline-based care and the disorders with randomized-trial support, as summarized in a 2017 review[2].

1Not all of these drugs are licensed for anxiety indications in every country[2].

2For specific phobia, the evidence base is exposure-based behavioral therapy; drug trials are very few[2].

Sources

  • •Bandelow et al., Dialogues in Clinical Neuroscience, 2017

Psychotherapy Options: CBT, Exposure and Other Approaches

CBT is the psychotherapy with the most evidence for anxiety disorders[2]. When avoidance of feared situations keeps the anxiety going, exposure to those situations is built into treatment[2].

A 2018 meta-analysis of 41 randomized trials in anxiety and related disorders, comparing CBT with a psychological or pill placebo, found a moderate effect on the target disorder (Hedges' g = 0.56)[1]. The odds of responding were nearly three times higher with CBT than with placebo (odds ratio 2.97)[1].

Effects differed by diagnosis: large for obsessive-compulsive disorder (g = 1.13) and generalized anxiety disorder (g = 1.01), and small to moderate for social anxiety disorder (g = 0.41) and panic disorder (g = 0.39)[1]. Individual CBT outperformed group CBT in the social anxiety studies[1]. Trial-by-trial detail is in social anxiety disorder treatments.

For specific phobias, the evidence comes from exposure-based behavioral therapy, and trials found that one to five sessions were often enough[2].

Other approaches have thinner evidence. Psychodynamic therapy has fewer and lower-quality controlled trials than CBT, and some head-to-head studies favored CBT[2]. Formats and session structure are covered in therapy for anxiety and exposure therapy.

Medication Options: First-Line Drugs, Alternatives and Benzodiazepines

SSRIs and SNRIs are the recommended first-line drugs because of their benefit/risk balance[2]. Their anti-anxiety effect starts after a lag of 2 to 4 weeks, sometimes up to 6, and jitteriness or a temporary rise in anxiety can occur in the first 2 weeks[2].

In around 75% of cases, doses in the lower part of the therapeutic range are sufficient[2]. Pregabalin, which has trial support in GAD and social anxiety, takes effect sooner than antidepressants and may improve sleep earlier[2].

Benzodiazepines work soon after a dose, but current guidelines do not recommend them as first-line treatment because of risks that include sedation, impaired driving and dependence after long-term use[2]. In 2020 the FDA required an updated boxed warning for the whole class covering abuse, misuse, addiction, physical dependence and withdrawal reactions[7].

About 92 million benzodiazepine prescriptions were dispensed from U.S. outpatient pharmacies in 2019, and in 2018 about half of patients given oral benzodiazepines received them for two months or longer[7]. Drug names, doses and side effects are covered in anxiety medication and SSRIs for anxiety.

How to read treatment comparisons: Drug trials usually compare against a pill placebo, while 70% to 75% of psychotherapy trials used a waitlist control, so the margin over control cannot be compared directly between the two[2]. Before-and-after (pre-post) effect sizes measure change within one group, so they also capture placebo response and natural improvement.

Therapy, Medication or Both?

No single option is best for everyone, and guidelines leave the choice to individual factors and preference[2]. In a meta-analysis of short-term trials covering about 35,000 patients, medications showed a larger average before-and-after improvement (Cohen's d = 2.02) than psychotherapies (d = 1.22)[2].

That comparison has two caveats: patients in psychotherapy trials were less severely ill, and pill placebo arms improved about as much as psychotherapy arms[2]. Combined psychotherapy and medication reached d = 2.12, but only a few combination trials were available[2].

The clearest head-to-head data come from children. In a trial of 488 children aged 7 to 17 with separation anxiety disorder, generalized anxiety disorder or social phobia, 80.7% were much or very much improved after 12 weeks of combined CBT and sertraline, compared with 59.7% on CBT alone, 54.9% on sertraline alone and 23.7% on placebo[3].

A side-by-side look at self-help, supplements and other approaches is in what helps with anxiety. Options for younger patients are covered in treatment for separation anxiety.

Where Treatment Happens: Primary Care, Specialty Clinics and Online

Much anxiety care starts in primary care. Since 2023, the USPSTF has recommended screening adults 64 and younger, including pregnant and postpartum people, with positive screens followed by evaluation and evidence-based care or referral[6].

Primary care can deliver specialist-level treatment with support. In the CALM trial across 17 primary care clinics in 4 U.S. cities, 1,004 patients chose CBT, medication or both, with care managers delivering computer-assisted CBT and helping adjust medicines[8].

At 12 months, 63.7% responded and 51.5% were in remission under this collaborative care model, compared with 44.7% and 33.3% in usual care[8].

Online CBT is now a tested format. A 2023 meta-analysis of 31 randomized trials found therapist-supported internet CBT produced effects similar to face-to-face CBT (pooled difference g = 0.02), with half the trials in depression or anxiety disorders[9]. Formats and costs are covered in anxiety online treatment.

What Happens When the First Treatment Doesn't Work

Before calling a case treatment-resistant, clinicians check that the diagnosis is right, the medicine was taken as prescribed, the dose covered the full range and the trial lasted long enough[2]. Apparent failures often turn out to be a drug given only at the lowest dose or stopped within the first 2 weeks because of early side effects[2].

If there is no response after 4 to 6 weeks at an adequate dose, guidelines advise changing the medication[2]. One analysis found the chance of responding after week 4 was 20% or less when no effect had appeared by week 2[2].

Next steps in guideline-based plans include switching to another SSRI, from an SSRI to an SNRI or the reverse, to a tricyclic antidepressant, or to pregabalin in GAD[2]. Adding CBT is generally recommended for people who do not respond to medication[2].

When standard options fail, some drugs are used off-label, such as quetiapine or agomelatine, but few systematic trials have studied treatment-refractory anxiety[2].

How Long Treatment Lasts and What Happens After It Stops

Guidelines advise continuing medication for 12 months or more after remission, then tapering over about 2 weeks to avoid withdrawal symptoms[2]. Almost no controlled studies cover treatment periods beyond 12 months[2].

A 2017 meta-analysis pooled 28 relapse-prevention trials (5,233 patients) in which people who had responded to an antidepressant were randomized to continue it or switch to placebo[4]. With up to one year of follow-up, 36.4% relapsed on placebo compared with 16.4% who continued[4].

The authors caution that the lack of data beyond one year is not advice to stop at one year, and they recommend basing treatment length on relapse risk, side effects and patient preference[4].

Therapy gains do not last for everyone either. In an analysis of 8 randomized CBT trials, 48% of patients were still symptomatic 2 to 14 years after treatment[2].

How Many People With Anxiety Disorders Get Treatment

Most people with an anxiety disorder never receive an adequate course of any of these options. In World Mental Health Surveys of 51,547 adults in 21 countries, 9.8% had an anxiety disorder in the past 12 months, and 27.6% of them received any treatment[5].

Only 9.8% received possibly adequate treatment, defined as at least 1 month of medication with 4 or more doctor visits, or at least 8 psychotherapy or other visits[5]. Just 41.3% of those with a past-year anxiety disorder perceived a need for care[5].

Help-seeking also varies by diagnosis. In U.S. survey data published in 1993, 54.4% of people with panic disorder with agoraphobia contacted health services in a year, compared with 27.3% of those with specific phobias[2]. Current U.S. figures are on the generalized anxiety disorder, panic disorder and social anxiety disorder pages.

People with a past-year anxiety disorder who received possibly adequate treatment, 21 countries
9.8%

Fewer than 3 in 10 received any treatment at all, and about 1 in 10 received care meeting minimum thresholds for medication follow-up or psychotherapy visits.

"only 9.8% received possibly adequate treatment"

Alonso et al., Depression and Anxiety(2018) View Source

Frequently Asked Questions

Sources & References

  1. Carpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JAJ, Hofmann SG. Cognitive behavioral therapy for anxiety and related disorders: a meta-analysis of randomized placebo-controlled trials. Depression and Anxiety. Published 2018. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC5992015/ [Link]
  2. Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues in Clinical Neuroscience. Published 2017. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC5573566/ [Link]
  3. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. New England Journal of Medicine. Published 2008. Accessed October 2026. https://www.nejm.org/doi/full/10.1056/NEJMoa0804633 [Link]
  4. Batelaan NM, Bosman RC, Muntingh A, Scholten WD, Huijbregts KM, van Balkom AJLM. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ. Published 2017. Accessed October 2026. https://www.bmj.com/content/358/bmj.j3927 [Link]
  5. Alonso J, Liu Z, Evans-Lacko S, et al. Treatment gap for anxiety disorders is global: results of the World Mental Health Surveys in 21 countries. Depression and Anxiety. Published 2018. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC6008788/ [Link]
  6. US Preventive Services Task Force. Anxiety Disorders in Adults: Screening. Final Recommendation Statement. Published 2023. Accessed October 2026. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening [Link]
  7. US Food and Drug Administration. FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. Published 2020. Accessed October 2026. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class [Link]
  8. Roy-Byrne P, Craske MG, Sullivan G, et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA. Published 2010. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC2928714/ [Link]
  9. Hedman-Lagerlöf E, Carlbring P, Svärdman F, Riper H, Cuijpers P, Andersson G. Therapist-supported Internet-based cognitive behaviour therapy yields similar effects as face-to-face therapy for psychiatric and somatic disorders: an updated systematic review and meta-analysis. World Psychiatry. Published 2023. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC10168168/ [Link]

Related Statistics